Vitamin D has reported anti-cancer and anti-inflammatory properties modulated through gene transcription and non-genomic signaling cascades. The purpose of this review was to summarize the available research on interactions and pharmacokinetics between vitamin D and the pharmaceutical drugs used in patients with cancer. Hypercalcemia was the most frequently reported side effect that occurred in high dose calcitriol. The half-life of 25(OH)D 3 and/or 1,25(OH) 2D 3 was found to be impacted by cimetidine; rosuvastatin; prednisone and possibly some chemotherapy drugs. No unusual adverse effects in cancer patients; beyond what is expected from high dose 1,25(OH) 2D 3 supplementation, were revealed through this review. While sufficient evidence is lacking, supplementation with 1,25(OH) 2D 3 during chemotherapy appears to have a low risk of interaction. Further interactions with vitamin D 3 have not been studied.
References
[1]
Wang, L.; Song, Y.; Manson, J.E.; Pilz, S.; Marz, W.; Michaelsson, K.; Lundqvist, A.; Jassal, S.K.; Barrett-Connor, E.; Zhang, C.; et al. Circulating 25-hydroxy-vitamin d and risk of cardiovascular disease: A meta-analysis of prospective studies. Circ. Cardiovasc. Qual. Outcomes 2012, 5, 819–829, doi:10.1161/CIRCOUTCOMES.112.967604.
[2]
Vanoirbeek, E.; Krishnan, A.; Eelen, G.; Verlinden, L.; Bouillon, R.; Feldman, D.; Verstuyf, A. The anti-cancer and anti-inflammatory actions of 1,25(OH)2D3. Baillieres Best Pract. Res. Clin. Endocrinol. Metab. 2011, 25, 593–604, doi:10.1016/j.beem.2011.05.001.
[3]
Lang, P.O.; Samaras, N.; Samaras, D.; Aspinall, R. How important is vitamin D in preventing infections? Osteoporos. Int. 2012, doi:10.1007/s00198-012-2204-6.
[4]
Holick, M.F. Vitamin D deficiency. N. Engl. J. Med. 2007, 357, 266–281, doi:10.1056/NEJMra070553.
[5]
Schottker, B.; Ball, D.; Gellert, C.; Brenner, H. Serum 25-hydroxyvitamin D levels and overall mortality. A systematic review and meta-analysis of prospective cohort studies. Ageing Res. Rev. 2012, doi:10.1016/j.arr.2012.02.004.
[6]
Plum, L.; DeLuca, H. The Functional metabolism and molecular biology of vitamin D action, 2nd ed.; Humana Press: New York, NY, USA, 2010; pp. 61–97, 1155.
[7]
Berry, D.; Hypponen, E. Determinants of vitamin D status: Focus on genetic variations. Curr. Opin. Nephrol. Hypertens. 2011, 20, 331–336, doi:10.1097/MNH.0b013e328346d6ba.
[8]
DeLuca, H.F. Evolution of our understanding of vitamin D. Nutr. Rev. 2008, 66, S73–S87, doi:10.1111/j.1753-4887.2008.00105.x.
[9]
Vieth, R. The mechanisms of vitamin D toxicity. Bone Miner. 1990, 11, 267–272, doi:10.1016/0169-6009(90)90023-9.
[10]
Jones, G. Pharmacokinetics of vitamin D toxicity. Am. J. Clin. Nutr. 2008, 88, 582S–586S.
[11]
Bolland, M.J.; Grey, A.; Avenell, A.; Gamble, G.D.; Reid, I.R. Calcium supplements with or without vitamin D and risk of cardiovascular events: Reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ 2011, 342, d2040.
[12]
Lappe, J.M.; Travers-Gustafson, D.; Davies, K.M.; Recker, R.R.; Heaney, R.P. Vitamin D and calcium supplementation reduces cancer risk: Results of a randomized trial. Am. J. Clin. Nutr. 2007, 85, 1586–1591.
[13]
Marshall, D.T.; Savage, S.J.; Garrett-Mayer, E.; Keane, T.E.; Hollis, B.W.; Horst, R.L.; Ambrose, L.H.; Kindy, M.S.; Gattoni-Celli, S. Vitamin D3 supplementation at 4,000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J. Clin. Endocrinol. Metab. 2012, 97, 2315–2324, doi:10.1210/jc.2012-1451.
[14]
Tretli, S.; Schwartz, G.G.; Torjesen, P.A.; Robsahm, T.E. Serum levels of 25-hydroxyvitamin D and survival in Norwegian patients with cancer of breast, colon, lung, and lymphoma: A population-based study. Cancer Causes Control 2012, 23, 363–370, doi:10.1007/s10552-011-9885-6.
[15]
Yin, L.; Grandi, N.; Raum, E.; Haug, U.; Arndt, V.; Brenner, H. Meta-analysis: Circulating vitamin D and ovarian cancer risk. Gynecol. Oncol. 2011, 121, 369–375, doi:10.1016/j.ygyno.2011.01.023.
[16]
Yin, L.; Grandi, N.; Raum, E.; Haug, U.; Arndt, V.; Brenner, H. Meta-analysis: Serum vitamin D and breast cancer risk. Eur. J. Cancer 2010, 46, 2196–2205, doi:10.1016/j.ejca.2010.03.037.
[17]
Yin, L.; Grandi, N.; Raum, E.; Haug, U.; Arndt, V.; Brenner, H. Meta-analysis: Longitudinal studies of serum vitamin D and colorectal cancer risk. Aliment. Pharmacol. Ther. 2009, 30, 113–125, doi:10.1111/j.1365-2036.2009.04022.x.
[18]
Trump, D.L.; Deeb, K.K.; Johnson, C.S. Vitamin D: Considerations in the continued development as an agent for cancer prevention and therapy. Cancer J. 2010, 16, 1–9, doi:10.1097/PPO.0b013e3181c51ee6.
[19]
Boulard, J.C.; Hanslik, T.; Alterescu, R.; Baglin, A. Symptomatic hypercalcemia after vitamin D-thiazide diuretics combination. Two cases in elderly women. Presse Med. 1994, 23, 96.
[20]
Cohen, H.J.; Silberman, H.R.; Tornyos, K.; Bartolucci, A.A. Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma. Blood 1984, 63, 639–648.
[21]
Srinivas, S.; Feldman, D. A phase II trial of calcitriol and naproxen in recurrent prostate cancer. Anticancer Res. 2009, 29, 3605–3610.
[22]
Beer, T.M.; Eilers, K.M.; Garzotto, M.; Egorin, M.J.; Lowe, B.A.; Henner, W.D. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J. Clin. Oncol. 2003, 21, 123–128, doi:10.1200/jco.2003.05.117.
[23]
Fakih, M.G.; Trump, D.L.; Muindi, J.R.; Black, J.D.; Bernardi, R.J.; Creaven, P.J.; Schwartz, J.; Brattain, M.G.; Hutson, A.; French, R.; et al. A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors. Clin. Cancer Res. 2007, 13, 1216–1223, doi:10.1158/1078-0432.CCR-06-1165.
[24]
Trump, D.L.; Hershberger, P.A.; Bernardi, R.J.; Ahmed, S.; Muindi, J.; Fakih, M.; Yu, W.-D.; Johnson, C.S. Anti-tumor activity of calcitriol: Pre-clinical and clinical studies. J. Steroid. Biochem. Mol. Biol. 2004, 89–90, 519–526.
[25]
Muindi, J.R.; Modzelewski, R.A.; Peng, Y.; Trump, D.L.; Johnson, C.S. Pharmacokinetics of 1α,25-Dihydroxyvitamin D3 in Normal Mice after Systemic Exposure to Effective and Safe Antitumor Doses. Oncology 2004, 66, 62–66, doi:10.1159/000076336.
[26]
Muindi, J.R.; Johnson, C.S.; Trump, D.L.; Christy, R.; Engler, K.L.; Fakih, M.G. A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors. Cancer Chemother. Pharmacol 2009, 65, 33–40, doi:10.1007/s00280-009-1000-2.
[27]
Petrioli, R.; Pascucci, A.; Francini, E.; Marsili, S.; Sciandivasci, A.; de Rubertis, G.; Barbanti, G.; Manganelli, A.; Salvestrini, F.; Francini, G. Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel. BJU Int. 2007, 100, 775–779, doi:10.1111/j.1464-410X.2007.07019.x.
[28]
Tiffany, N.M.; Ryan, C.W.; Garzotto, M.; Wersinger, E.M.; Beer, T.M. High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: A phase I/II study. J. Urol. 2005, 174, 888–892, doi:10.1097/01.ju.0000169261.42298.e6.
[29]
Avioli, L.V.; Birge, S.J.; Lee, S.W. Effects of prednisone on vitamin D metabolism in man. J. Clin. Endocrinol. Metab. 1968, 28, 1341–1346, doi:10.1210/jcem-28-9-1341.
[30]
Muindi, J.R.; Peng, Y.; Potter, D.M.; Hershberger, P.A.; Tauch, J.S.; Capozzoli, M.J.; Egorin, M.J.; Johnson, C.S.; Trump, D.L. Pharmacokinetics of high-dose oral calcitriol: Results from a phase 1 trial of calcitriol and paclitaxel. Clin. Pharmacol. Ther. 2002, 72, 648–659.
[31]
Yavuz, B.; Ertugrul, D.T.; Cil, H.; Ata, N.; Akin, K.O.; Yalcin, A.A.; Kucukazman, M.; Dal, K.; Hokkaomeroglu, M.S.; Yavuz, B.B.; et al. Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: A novel pleiotropic effect of statins? Cardiovasc. Drugs Ther. 2009, 23, 295–299, doi:10.1007/s10557-009-6181-8.
[32]
Ertugrul, D.T.; Yavuz, B.; Cil, H.; Ata, N.; Akin, K.O.; Kucukazman, M.; Yalcin, A.A.; Dal, K.; Yavuz, B.B.; Tutal, E. STATIN-D Study: Comparison of the Influences of Rosuvastatin and Fluvastatin Treatment on the Levels of 25 Hydroxyvitamin D. Cardiovasc. Ther. 2011, 29, 146–152, doi:10.1111/j.1755-5922.2010.00141.x.
[33]
Odes, H.S.; Fraser, G.M.; Krugliak, P.; Lamprecht, S.A.; Shany, S. Effect of cimetidine on hepatic vitamin D metabolism in humans. Digestion 1990, 46, 61–64, doi:10.1159/000200333.
[34]
Gao, Y.; Shimizu, M.; Yamada, S.; Ozaki, Y.; Aso, T. The effects of chemotherapy including cisplatin on vitamin D metabolism. Endocr. J. 1993, 40, 737–742.
[35]
Fakih, M.G.; Trump, D.L.; Johnson, C.S.; Tian, L.; Muindi, J.; Sunga, A.Y. Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancer. Int. J. Colorectal Dis. 2009, 24, 219–224.
[36]
Jacot, W.; Pouderoux, S.; Thezenas, S.; Chapelle, A.; Bleuse, J.P.; Romieu, G.; Lamy, P.J. Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy. Breast Cancer Res. Treat. 2012, 2, 709–711.
[37]
Petkovish, M.; Helvig, C.; Epps, T. CYP24A1 Regulation in health and disease. In Vitamin D, 3rd; Feldman, D., Pike, J.W.S., Adams, J., Eds.; Elsevier Science & Technology Books: San Diego, CA, USA, 2011; p. 2144.
[38]
Farhan, H.; Wahala, K.; Cross, H.S. Genistein inhibits vitamin D hydroxylases CYP24 and CYP27B1 expression in prostate cells. J. Steroid. Biochem. Mol. Biol. 2003, 84, 423–429, doi:10.1016/S0960-0760(03)00063-3.
[39]
Wang, Z.; Lin, Y.S.; Zheng, X.E.; Senn, T.; Hashizume, T.; Scian, M.; Dickmann, L.J.; Nelson, S.D.; Baillie, T.A.; Hebert, M.F.; et al. An inducible cytochrome P450 3A4-dependent vitamin D catabolic pathway. Mol. Pharmacol. 2012, 81, 498–509.
[40]
International Clinical Trials Search Portal: Registry Platform. Version 3.2. Available online: http://apps.who.int/trialsearch/ (accessed on 15 February 2013).
[41]
metaRegister of Controlled Trials (mRCT). Available online: http://www.controlled-trials.com/mrct/ (accessed on 15 February 2013).
[42]
Sampson, M.; McGowan, J.; Cogo, E.; Grimshaw, J.; Moher, D.; Lefebvre, C. An evidence-based practice guideline for the peer review of electronic search strategies. J. Clin. Epidemiol. 2009, 62, 944–952, doi:10.1016/j.jclinepi.2008.10.012.
[43]
Hellstrom, E.; Robert, K.H.; Gahrton, G.; Mellstedt, H.; Lindemalm, C.; Einhorn, S.; Bjorkholm, M.; Grimfors, G.; Uden, A.M.; Samuelsson, J.; et al. Therapeutic effects of low-dose cytosine arabinoside, alpha-interferon, 1 alpha-hydroxyvitamin d3 and retinoic acid in acute leukemia and myelodysplastic syndromes. Eur. J. Haematol. 1988, 40, 449–459.
[44]
Slapak, C.A.; Desforges, J.F.; Fogaren, T.; Miller, K.B. Treatment of acute myeloid leukemia in the elderly with low-dose cytarabine, hydroxyurea, and calcitriol. Am. J. Hematol. 1992, 41, 178–183, doi:10.1002/ajh.2830410307.
[45]
Beer, T.M.; Eilers, K.M.; Garzotto, M.; Egorin, M.J.; Lowe, B.A.; Henner, W.D. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J. Clin. Oncol. 2003, 21, 123–128, doi:10.1200/jco.2003.05.117.
[46]
Beer, T.M.; Garzotto, M.; Katovic, N.M. High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer. Am. J. Clin. Oncol. 2004, 27, 535–541, doi:10.1097/01.coc.0000136020.27904.9c.
[47]
Morris, M.J.; Smaletz, O.; Solit, D.; Kelly, W.K.; Slovin, S.; Flombaum, C.; Curley, T.; Delacruz, A.; Schwartz, L.; Fleisher, M.; et al. High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma. Cancer 2004, 100, 1868–1875, doi:10.1002/cncr.20185.
[48]
Trump, D.L.; Potter, D.M.; Muindi, J.; Brufsky, A.; Johnson, C.S. Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin d3) and dexamethasone in androgen-independent prostate cancer. Cancer 2006, 106, 2136–2142, doi:10.1002/cncr.21890.
[49]
Beer, T.M.; Ryan, C.W.; Venner, P.M.; Petrylak, D.P.; Chatta, G.S.; Ruether, J.D.; Redfern, C.H.; Fehrenbacher, L.; Saleh, M.N.; Waterhouse, D.M.; et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ascent investigators. J. Clin. Oncol. 2007, 25, 669–674, doi:10.1200/JCO.2006.06.8197.
[50]
Chan, J.S.; Beer, T.M.; Quinn, D.I.; Pinski, J.K.; Garzotto, M.; Sokoloff, M.; Dehaze, D.R.; Ryan, C.W. A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer. BJU Int. 2008, 102, 1601–1606, doi:10.1111/j.1464-410X.2008.08017.x.
[51]
Beer, T.M.; Ryan, C.W.; Venner, P.M.; Petrylak, D.P.; Chatta, G.S.; Ruether, J.D.; Chi, K.N.; Young, J.; Henner, W.D. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: Results from ascent, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer 2008, 112, 326–330, doi:10.1002/cncr.23163.
[52]
Blanke, C.D.; Beer, T.M.; Todd, K.; Mori, M.; Stone, M.; Lopez, C. Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic cancer. Invest. New Drugs 2009, 27, 374–378, doi:10.1007/s10637-008-9184-6.
[53]
Chadha, M.K.; Tian, L.; Mashtare, T.; Payne, V.; Silliman, C.; Levine, E.; Wong, M.; Johnson, C.; Trump, D.L. Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer. Cancer 2010, 116, 2132–2139.
[54]
Scher, H.I.; Jia, X.; Chi, K.; de Wit, R.; Berry, W.R.; Albers, P.; Henick, B.; Waterhouse, D.; Ruether, D.J.; Rosen, P.J.; et al. Randomized, open-label phase iii trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J. Clin. Oncol. 2011, 29, 2191–2198, doi:10.1200/JCO.2010.32.8815.
